Abstract
Background Among LRRK2-associated parkinsonism cases with nigral degeneration, over two-thirds demonstrate evidence of pathologic alpha-synuclein, but many do not. Understanding the clinical phenotype and underlying biology in such individuals is critical for therapeutic development. Our objective was to compare clinical and biomarker features, and rate of progression over 4 years follow-up, among LRRK2-associated parkinsonism cases with and without in vivo evidence of alpha-synuclein aggregates.
Methods Data were from the Parkinson’s Progression Markers Initiative, a multicenter prospective cohort study. The sample included individuals diagnosed with Parkinson disease with pathogenic variants in LRRK2. Presence of CSF alpha-synuclein aggregation was assessed with seed amplification assay. A range of clinician– and patient-reported outcome assessments were administered. Biomarkers included dopamine transporter SPECT scan, CSF amyloid-beta1-42, total tau, phospho-tau181, urine bis(monoacylglycerol)phosphate levels, and serum neurofilament light chain. Linear mixed effects models examined differences in trajectory in CSF negative and positive groups.
Results 148 LRRK2-parkinsonism cases (86% with G2019S variant), 46 negative and 102 positive for CSF alpha-synuclein seed amplification assay were included. At baseline, the negative group were older than the positive group (median [interquartile range] 69.1 [65.2-72.3] vs 61.5 [55.6-66.9] years, p<0.001) and a greater proportion were female (28 (61%) vs 43 (42%), p=0.035). Despite being older, the negative group had similar duration since diagnosis, and similar motor rating scale (16 [11-23] vs 16 [10-22], p=0.480) though lower levodopa equivalents. Only 13 (29%) of the negative group were hyposmic, compared to 75 (77%) of the positive group. Lowest putamen dopamine transporter binding expected for age and sex was greater in the negative vs positive groups (0.36 [0.29-0.45] vs 0.26 [0.22-0.37], p<0.001). Serum neurofilament light chain was higher in the negative group compared to the positive group (17.10 [13.60-22.10] vs 10.50 [8.43-14.70]; age-adjusted p-value=0.013). In terms of longitudinal change, the negative group remained stable in functional rating scale score in contrast to the positive group who had a significant increase (worsening) of 0.729 per year (p=0.037), but no other differences in trajectory were found.
Conclusion Among individuals diagnosed with Parkinson disease with pathogenic variants in the LRRK2 gene, we found clinical and biomarker differences in cases without versus with in vivo evidence of CSF alpha-synuclein aggregates. LRRK2 parkinsonism cases without evidence of alpha-synuclein aggregates as a group exhibit less severe motor manifestations and decline may have more significant cognitive dysfunction. The underlying biology in LRRK2-parkinsonism cases without evidence of alpha-synuclein aggregates requires further investigation.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://dx.doi.org/10.17504/protocols.io.n92ldmw6ol5b/v2
Funding Statement
PPMI, a public-private partnership, is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, including 4D Pharma, Abbvie, AcureX, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson’s, AskBio, Avid Radiopharmaceuticals, BIAL, BioArctic, Biogen, Biohaven, BioLegend, BlueRock Therapeutics, Bristol-Myers Squibb, Calico Labs, Capsida Biotherapeutics, Celgene, Cerevel Therapeutics, Coave Therapeutics, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Golub Capital, Handl Therapeutics, Insitro, Jazz Pharmaceuticals, Johnson & Johnson Innovative Medicine, Lundbeck, Merck, Meso Scale Discovery, Mission Therapeutics, Neurocrine Biosciences, Neuron23, Neuropore, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi, Servier, Sun Pharma Advanced Research Company, Takeda, Teva, UCB, Vanqua Bio, Verily, Voyager Therapeutics, the Weston Family Foundation and Yumanity Therapeutics. This work was supported in part by the Intramural Research Program of the National Institute on Aging (NIA) and the Center for Alzheimer’s and Related Dementias (CARD) under Award Number AG000534 H.I.’s participation in this project was part of a competitive contract awarded to DataTecnica LLC by the National Institutes of Health to support open science research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data used in the preparation of this article were obtained on January 8, 2024 from the Parkinson’s Progression Markers Initiative (PPMI) database (www.ppmi-info.org/access-data-specimens/download-data), RRID:SCR 006431. For up-to-date information on the study, visit www.ppmi-ifo.org.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Abbreviations
- AD
- Alzheimer’s Disease
- AMP-PD
- Accelerating Medicines Partnership Parkinson’s Disease
- Asyn
- Alpha-synuclein
- BMP
- Bis(monoacylglycero)phosphate
- CBD
- Corticobasal Degeneration
- CSF
- Cerebrospinal fluid
- CSFasynSAA+
- Positive CSF asyn SAA
- CSFasynSAA−
- Negative CSF asyn SAA
- DAT
- Dopamine transporter binding
- DLB
- Dementia with Lewy Bodies
- ESS
- Epworth Sleepiness Scale
- FTD
- Familial Frontotemporal Degeneration
- GDS-15
- Geriatric Depression Scale-15 item
- GWAS
- Genome-wide Association Studies
- HVLT-R
- Hopkins Verbal Learning Test-Revised
- LEDD
- Levodopa equivalent daily dose
- LMM
- Linear mixed-effects models
- MAR
- Missing at random
- MCI
- Mild Cognitive Impairment
- MDS-UPDRS
- Movement Disorders Society Modified Unified Parkinson’s Disease Rating Scale
- MoCA
- Montreal Cognitive Assessment
- mPRS
- Modified polygenic risk score
- MSA
- Multiple System Atrophy
- Nfl
- Neurofilament light
- PD
- Parkinson’s Disease
- PPMI
- Parkinson Progression Markers Initiative
- PRS
- Polygenic risk score
- PSP
- Progressive Supranuclear Palsy
- QUIP-RS
- Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease–Rating Scale
- RBD
- Rapid Eye Movement Behavior Disorder
- SAA
- Seed amplification assay
- SBR
- Specific binding ratio
- SCOPA-AUT
- Scales for Outcomes in Parkinson’s-Autonomic
- SNP
- Single-nucleotide polymorphism
- sPD
- Sporadic Parkinson’s Disease
- SPECT
- Single-photon emission computed tomography
- STAI
- State and Trait Anxiety Scale
- TDP-43
- TAR DNA-binding protein 43
- UPSIT
- University of Pennsylvania Smell Identification Test
